Compare Ascendis Pharma A/S (ASND) vs Autozone Inc (AZO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Autozone Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Autozone Inc trades at $3,072 (market cap $50.16B). The key difference: Autozone Inc is far larger — about 2.8× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Autozone Inc nearer its low. Which is the better fit depends on your goals.
| ASND | AZO | |
|---|---|---|
Market Cap | $17.74B | $50.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $4.35K |
52-Week Low | $163.32 | $2.94K |
Enterprise Value | $18.11B | $62.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
AutoZone (AZO) trades at $3,072.64, up 2.07% today, amid a bearish technical signal but strong analyst support. Recent earnings show mixed quarterly beats, with Q2 2026 results pending. Revenue has grown steadily to $18.94B in 2025, though net income margins are declining. The company continues aggressive share buybacks and international expansion, with a consensus price target of $3,740.
The outlook is cautiously optimistic, driven by buyback programs and commercial momentum, but risks include competitive pressures and margin compression. With 73% of analysts rating it a Buy, the stock offers value if execution aligns with expansion plans, though investors should monitor same-store sales trends and macroeconomic impacts on discretionary spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →
